Why the study?
Do inhaled anticholinergics increase the risk of cardiovascular adverse events in patients with COPD?
Do inhaled anticholinergics increase the risk of cardiovascular adverse events in patients with COPD?
Answers are grounded in this paper and cite their sources.
This review concludes that inhaled anticholinergics used for COPD do not increase the risk of cardiovascular adverse events, reassuring their cardiovascular safety profile.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
L Nagy (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: